Journal article

Common Breast Cancer Susceptibility Variants in LSP1 and RAD51L1 Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk

Celine M Vachon, Christopher G Scott, Peter A Fasching, Per Hall, Rulla M Tamimi, Jingmei Li, Jennifer Stone, Carmel Apicella, Fabrice Odefrey, Gretchen L Gierach, Sebastian M Jud, Katharina Heusinger, Matthias W Beckmann, Marina Pollan, Pablo Fernandez-Navarro, Anna Gonzalez-Neira, Javier Benitez, Carla H van Gils, Mariette Lokate, N Charlotte Onland-Moret Show all

Cancer Epidemiology, Biomarkers & Prevention | AMER ASSOC CANCER RESEARCH | Published : 2012

Related Projects (1)

Grants

Awarded by National Health and Medical Research Council (NHMRC)


Awarded by Spain's Health Research Fund (Fond de Investigacio'n Sanitaria)


Awarded by Collaboration Agreement between Astra-Zeneca


Awarded by Cancer Research UK


Awarded by National Cancer Institute, NIH (Bethesda, MD)


Awarded by California Breast Cancer Research Program of the University of California


Awarded by National Institute of Environmental Health Sciences, NIH


Awarded by UK Medical Research Council


Awarded by Public Health Service from the National Cancer institute, NIH, Department of Health and Human Services


Awarded by National Cancer Institute


Awarded by Norwegian Research Council


Awarded by Norwegian Cancer Society


Awarded by South Eastern Norway Regional Health Authority


Awarded by U.S. National Cancer Institute, NIH under REA (Cancer Care Ontario)


Awarded by Norway through the Polish - Norwegian Research Fund


Awarded by Medical Research Council


Awarded by National Institute for Health Research


Funding Acknowledgements

MOG: The authors acknowledge NHS funding to the NIHR Royal Marsden Biomedical Research Centre.AMDTSS: This research was facilitated through access to the Australian Twin Registry, a national resource supported by an Enabling grant (ID 628911) from the National Health and Medical Research Council (NHMRC) and supported by grants from the NHMRC and National Breast Cancer Foundation/Cancer Australia.BBCC: This study was funded, in part, by the ELAN-Program of the University Hospital Erlangen (Erlangen, Germany); K. Heusinger was funded by the ELAN program of the University Hospital Erlangen.DDM-Spain: This study was supported by Research Grant FIS PI060386 from Spain's Health Research Fund (Fond de Investigacio'n Sanitaria); the EPY 1306/06 Collaboration Agreement between Astra-Zeneca and the Institut de Salud Carlos III; and a grant from the Spanish Federation of Breast Cancer (FECMA).EPIC-NI: This study was funded by "Europe against Cancer" Programme of the European Commission (SANCO), Dutch Ministry of Health, Dutch Cancer Society, ZonMW the Netherlands Organisation for Health Research and Development, and the World Cancer Research Fund (WCRF).EPIC-Norfolk I: This study was funded by research program grant funding from Cancer Research UK and the Medical Research Council with additional support from the Stroke Association, British Heart Foundation, UK Department of Health, Research into Ageing and Academy of Medical Sciences.EPIC-Norfolk II: This study was funded by Cancer Research UK. LIFE: This study was supported by grants CA17054 and CA74847 from the National Cancer Institute, NIH (Bethesda, MD), 4PB-0092 from the California Breast Cancer Research Program of the University of California, and in part through contract no. N01-PC-35139, and T32 ES-013678 from the National Institute of Environmental Health Sciences, NIH. The collection of cancer incidence data used in this publication was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885.MARIBS: This study was funded by a Cancer Research UK project grant (C11518/A5644). The genetic studies were funded by Cancer Research UK as a separate project grant (C5047/A5830). The main MARIBS study was supported by a grant from the UK Medical Research Council (G9600413). S.J. Ramus was funded by the Mermaid arm of the Eve Appeal.MCBCS: This study was supported by Public Health Service Grants P50 CA 116201, R01 CA 128931, R01 CA 128931-S01, R01 CA 122340 from the National Cancer institute, NIH, Department of Health and Human Services.MCCS: The study was supported by the Cancer Council of Victoria and by the Victorian Breast Cancer Research ConsortiumMEC: The study was supported by National Cancer Institute grants R37CA054281, R01CA063464, R01CA085265 R25CA090956, and R01CA132839.MOG: This study was supported by program and project grants from Cancer Research UK and Breast Cancer Campaign.NBCS: This study has been supported with grants to V.N. Kristensen and A.-L. Borresen-Dale from Norwegian Research Council (#183621/S10 and #175240/S10), The Norwegian Cancer Society (PK80108002, PK60287003), and The Radium Hospital Foundation as well as S-02036 from South Eastern Norway Regional Health Authority.NHS: This study was supported by Public Health Service Grants CA131332, CA087969, CA089393, CA049449, CA98233 from the National Cancer Institute, NIH, Department of Health and Human Services.OFBCR: This work was supported by the U.S. National Cancer Institute, NIH under REA #CA-06-503 (Cancer Care Ontario U01 CA69467) and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators.PBCS: This study was supported by the Intramural Research Program of the U.S. National Cancer Institute, Department of Health and Human Services.PNS: The project was supported by a grant from Norway through the Polish - Norwegian Research Fund (PNRE-243-AI-1/07).SASBAC: The SASBAC study was supported by Marit and Hans Rausing's Initiative against Breast Cancer, National Institutes of Health, Susan Komen Foundation and Agency for Science, Technology and Research of Singapore (A*STAR).